Transcatheter arterial chemoembolization based on hepatic hemodynamics for hepatocellular carcinoma.
Transcatheter arterial chemoembolization based on hepatic hemodynamics for hepatocellular carcinoma.
复制标题
基于肝细胞癌的肝血液动力学基于经导管动脉化学栓塞。
DOI：
10.1155/2013/479805
复制
发表时间：
2013
影响因子：
--
通讯作者：
Kumita S
中科院分区：
文献类型：
--
作者：
Murata S;Mine T;Ueda T;Nakazawa K;Onozawa S;Yasui D;Kumita S
肝细胞癌（HCC）是世界上第六大常见癌症，也是癌症相关死亡的第三大原因。巴塞罗那临床肝癌 (BCLC) 分类最近已成为 HCC 患者临床管理的标准分类系统。根据BCLC分期系统，治愈性治疗（切除、移植和经皮消融）可以提高早期诊断的HCC患者的生存率，并提供潜在的长期疗效。中期 HCC 患者受益于经导管动脉化疗栓塞 (TACE)，而晚期诊断患者则接受索拉非尼（一种多激酶抑制剂）或保守治疗。大多数患者仅接受姑息或保守治疗，大约 50% 的 HCC 患者适合全身治疗。 TACE 通常被推荐给世界各地的晚期 HCC 患者，因为这些患者希望得到比全身化疗或保守治疗更有效的治疗。本文旨在总结 TACE 已发表的数据和正在进行的重要研究，并讨论晚期 HCC 的 TACE 技术改进。
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer-related deaths in the world. The Barcelona Clinic Liver Cancer (BCLC) classification has recently emerged as the standard classification system for clinical management of patients with HCC. According to the BCLC staging system, curative therapies (resection, transplantation, and percutaneous ablation) can improve survival in HCC patients diagnosed at an early stage and offer potential long-term curative effects. Patients with intermediate-stage HCC benefit from transcatheter arterial chemoembolization (TACE), and those diagnosed at an advanced stage receive sorafenib, a multikinase inhibitor, or conservative therapy. Most patients receive palliative or conservative therapy only, and approximately 50% of patients with HCC are candidates for systemic therapy. TACE is often recommended for advanced-stage HCC patients all over the world because these patients desire therapy that is more effective than systemic chemotherapy or conservative treatment. This paper aims to summarize both the published data and important ongoing studies for TACE and to discuss technical improvements in TACE for advanced-stage HCC.